Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).

被引：43

作者：

Antonia, Scott Joseph

Brahmer, Julie R.

Gettinger, Scott N.

Chow, Laura Quan Man

Juergens, Rosalyn A.

Shepherd, Frances A.

Laurie, Scott Andrew

Gerber, David E.

Goldman, Jonathan Wade

Shen, Yun

Harbison, Christopher

Alaparthy, Suresh

Chen, Allen C.

Borghaei, Hossein

Rizvi, Naiyer A.

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[3] Yale Canc Ctr, New Haven, CT USA

[4] Univ Washington, Seattle, WA 98195 USA

[5] Juravinski Canc Ctr, Hamilton, ON, Canada

[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[7] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[8] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[9] Univ Calif Los Angeles, Los Angeles, CA USA

[10] Bristol Myers Squibb Co, Princeton, NJ USA

[11] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[12] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.8113

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8113

引用

页数：1